Phase 1 Trial of SYNC-T Immunotherapy Reports Longer-Term Survival Data in Prostate Cancer

/in , , /by

Updated results provide longer-term survival data for SYNC-T Therapy SV-102, an experimental personalized immunotherapy evaluated in patients with metastatic prostate cancer. SYNC-T uses a two-step approach. First, a selected tumor lesion undergoes partial cryolysis, releasing patient-specific tumor antigens. An immunotherapy mixture called SV-102 is then injected directly into the treated area. It contains four components: […]

Read more

Phase 2 ExBAT Trial: AR Amplification Linked to Poorer Outcomes With Alternating Testosterone and Darolutamide

/in , , /by

New biomarker findings from the phase 2 ExBAT trial, suggest that androgen receptor (AR) amplification may be associated with poorer outcomes in patients receiving alternating bipolar androgen therapy (BAT) and darolutamide for metastatic castration-resistant prostate cancer (mCRPC). ExBAT/LACOG 0620 investigated an experimental strategy combining periods of supraphysiological testosterone exposure with subsequent androgen receptor inhibition. Patients […]

Read more

Phase 1 Trial: Astatine-211 PSMA-5 Shows Strong Early Responses in First-in-Human Prostate Cancer Trial

/in , , /by

Encouraging results suggest that 211At-PSMA-5, an experimental alpha-emitting radioligand targeting PSMA, may offer a promising new treatment approach for patients with metastatic castration-resistant prostate cancer (mCRPC). The findings come from a first-in-human phase 1 study involving 15 patients whose disease had progressed following androgen receptor pathway inhibitors and taxane-based chemotherapy. Unlike established PSMA-targeted radioligand therapy […]

Read more

Phase 2 Trial: DLL3 PET Reveals Tumor Heterogeneity in Neuroendocrine Prostate Cancer

/in , , /by

New findings suggest that an experimental PET imaging technique targeting DLL3 could help identify neuroendocrine prostate cancer (NEPC) lesions and reveal important differences between metastases within the same patient. Neuroendocrine prostate cancer is an aggressive form of the disease that can emerge following prolonged treatment with androgen receptor-targeted therapies. These tumors frequently show reduced PSMA […]

Read more

Phase 1 Trial for SHR-4394: PSMA-Targeted ADC Shows Early Activity in Advanced Prostate Cancer

/in , , /by

New results provide encouraging preliminary evidence of antitumor activity for SHR-4394, an investigational antibody-drug conjugate (ADC) targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). The findings come from a first-in-human 1hase 1 study evaluating SHR-4394 as a standalone treatment. The drug is designed to recognize PSMA, a protein frequently expressed on prostate cancer cells, and […]

Read more

UPDATE: TALAPRO-3, New Analysis Explores Talazoparib Benefit Across HRR Gene Mutations

/in , /by

New exploratory biomarker findings from the phase 3 TALAPRO-3 trial, provide further insight into how patients with different DNA repair gene alterations respond to the combination of talazoparib and enzalutamide in metastatic castration-sensitive prostate cancer (mCSPC). TALAPRO-3 previously demonstrated a significant improvement in radiographic progression-free survival (rPFS) with the addition of the PARP inhibitor talazoparib […]

Read more

UPDATE: ABBV-969 Shows Strong Molecular Responses in Advanced Prostate Cancer

/in , , /by

New biomarker data provide additional evidence of the preliminary activity of ABBV-969, an investigational antibody-drug conjugate (ADC) designed to target both PSMA and STEAP1 in metastatic castration-resistant prostate cancer (mCRPC). The findings come from the ongoing Phase 1 study, involving 49 heavily pretreated patients who had received a median of five previous treatment lines. Most […]

Read more

UPDATE: ²²⁵Ac-LNC1011 Achieves 86.7% PSA50 Response in Early mCRPC Study

/in , , /by

New results presented at EANM 2026 provide further evidence of the preliminary clinical activity of ²²⁵Ac-LNC1011, an experimental PSMA-targeted alpha radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). We have previously discussed this therapy in this post. Following the initial results, the new prospective study includes 15 patients previously treated with androgen receptor pathway inhibitors […]

Read more

ZZ-FIRST Trial: Adding Talazoparib to Enzalutamide Shows No Clear Additional Benefit in Metastatic Prostate Cancer

/in , , /by

A randomised phase 2 trial published in Nature Medicine has investigated whether adding the PARP inhibitor talazoparib to enzalutamide and androgen deprivation therapy (ADT) can improve outcomes in men with high-volume metastatic hormone-sensitive prostate cancer (mHSPC), regardless of their homologous recombination repair (HRR) mutation status. The study, known as ZZ-FIRST enrolled 54 patients across eight […]

Read more

Phase 2 Trial Tests Tinengotinib With Darolutamide or Enzalutamide in Hormone-Resistant Prostate Cancer

/in , , /by

A newly registered phase 2 clinical trial will investigate whether combining tinengotinib (TT-00420) with darolutamide or enzalutamide can improve disease control in men with metastatic castration-resistant prostate cancer (mCRPC). Tinengotinib is an oral multikinase inhibitor targeting several pathways involved in cancer growth and survival, including FGFR, JAK, VEGFR and Aurora kinases. Unlike darolutamide and enzalutamide, […]

Read more